These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38847725)
1. The potential mechanism of HIF-1α and CD147 in the development of triple-negative breast cancer. Chen M; Liu Z; Zheng K; Hu C; Peng P Medicine (Baltimore); 2024 Jun; 103(23):e38434. PubMed ID: 38847725 [TBL] [Abstract][Full Text] [Related]
2. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc. Cui J; Jiang H Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739 [TBL] [Abstract][Full Text] [Related]
3. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts. Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195 [TBL] [Abstract][Full Text] [Related]
4. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy. Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764 [TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA (lncRNA) metallothionein 1 J, pseudogene (MT1JP) is downregulated in triple-negative breast cancer and upregulates microRNA-138 (miR-138) to downregulate hypoxia-inducible factor-1α (HIF-1α). Wang G; Dong Y; Liu H; Ji N; Cao J; Liu A; Tang X; Ren Y Bioengineered; 2022 May; 13(5):13718-13727. PubMed ID: 35703312 [TBL] [Abstract][Full Text] [Related]
6. CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer. Liu M; Tsang JYS; Lee M; Ni YB; Chan SK; Cheung SY; Hu J; Hu H; Tse GMK J Clin Pathol; 2018 Nov; 71(11):1007-1014. PubMed ID: 30099407 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia-induced autophagy in triple negative breast cancer: association with prognostic variables, patients' survival and response to neoadjuvant chemotherapy. El-Guindy DM; Ibrahim FM; Ali DA; El-Horany HE; Sabry NM; Elkholy RA; Mansour W; Helal DS Virchows Arch; 2023 May; 482(5):823-837. PubMed ID: 36939902 [TBL] [Abstract][Full Text] [Related]
8. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Zhao S; Ma W; Zhang M; Tang D; Shi Q; Xu S; Zhang X; Liu Y; Song Y; Liu L; Zhang Q Med Oncol; 2013 Mar; 30(1):335. PubMed ID: 23263825 [TBL] [Abstract][Full Text] [Related]
9. MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147. Wang C; Xu C; Niu R; Hu G; Gu Z; Zhuang Z BMC Cancer; 2019 Jun; 19(1):577. PubMed ID: 31196010 [TBL] [Abstract][Full Text] [Related]
10. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy. Liu Q; Guan C; Liu C; Li H; Wu J; Sun C Biomed Pharmacother; 2022 Dec; 156():113861. PubMed ID: 36228375 [TBL] [Abstract][Full Text] [Related]
11. Subcellular expression of MTA1, HIF1A and p53 in primary tumor predicts aggressive triple negative breast cancers: a meta-analysis based study. Sharaf SS; Jaganath Krishna KM; Lekshmi A; Sujathan J Mol Histol; 2024 Jun; 55(3):303-315. PubMed ID: 38613589 [TBL] [Abstract][Full Text] [Related]
12. [Expression of hypoxia-inducible factor 1α in gastric cancer and its clinical signficance]. Wu YL; Hu LN; Zheng CD; Sun RC; Zhang SX; Yan Q; Li YX Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1418-23. PubMed ID: 27266349 [TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of MTDH and VEGF in triple-negative breast cancer]. Tan L; Qin H; Piao Y; Liu Z; Han Y; Song F; Xie X Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):827-32. PubMed ID: 26887512 [TBL] [Abstract][Full Text] [Related]
14. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
15. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer. Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701 [TBL] [Abstract][Full Text] [Related]
16. Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma. Huang C; Sun Z; Sun Y; Chen X; Zhu X; Fan C; Liu B; Zhao Y; Zhang W Histopathology; 2012 Apr; 60(5):793-803. PubMed ID: 22320715 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer. Zhang J; Wu Y; Lin YH; Guo S; Ning PF; Zheng ZC; Wang Y; Zhao Y World J Gastroenterol; 2018 Jun; 24(22):2381-2391. PubMed ID: 29904245 [TBL] [Abstract][Full Text] [Related]
18. Hypoxia-mediated activation of hypoxia-inducible factor-1α in triple-negative breast cancer: A review. Liu L; Bai J; Hu L; Jiang D Medicine (Baltimore); 2023 Oct; 102(43):e35493. PubMed ID: 37904441 [TBL] [Abstract][Full Text] [Related]
19. [Expression of hypoxia-inducible factor 1α is associated with lymph node metastasis in oral squamous cell carcinoma]. Li JN; Feng ZE; Wang L; Wang YX; Guo CB Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Feb; 50(1):26-32. PubMed ID: 29483718 [TBL] [Abstract][Full Text] [Related]
20. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]